Alkermes grants CEO stock options at $49.61

Alkermes plc reported that President & CEO Jackson Blair Curtis received two grants of Employee Stock Options on 2026-08-05.

Rhea-AI Filing Summary

Alkermes plc reported that President & CEO Jackson Blair Curtis received two grants of Employee Stock Options on 2026-08-05. One award covers 93,229 options with an exercise price of $49.6100 per share, vesting in four equal annual installments commencing on 8/5/2027 and expiring on 2036-08-05. A second award covers 124,305 options at the same exercise price and expiration, vesting in two tranches only if Alkermes’s ordinary share trades at certain pre-specified price levels for 30 consecutive trading days and after two years of continuous service as CEO, or less in the event of a change in control.

Insider Trade Summary

Grant/Award: 217,534 shares

Grant/Award 2 txns

Insider Jackson Blair Curtis

Role President & CEO, Alkermes plc

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (Right to Buy) F1, F2	93,229	$0.00	$0.00
Grant/Award	Employee Stock Option (Right to Buy) F1, F3	124,305	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (Right to Buy) — 217,534 contracts (Direct)

Footnotes (3)

1. F1. This award was granted in connection with the reporting person's appointment as President and Chief Executive Officer.
2. F2. Shares underlying the stock option vest and become exercisable in four equal annual installments, commencing on 8/5/2027.
3. F3. Shares underlying the stock option shall vest and become exercisable, if at all, in two tranches based upon the closing price of an ordinary share of Alkermes plc, as reported by the Nasdaq Global Select Market or another national securities exchange on which Alkermes plc's ordinary shares are listed, trading at certain pre-specified levels for 30 consecutive trading days, subject in each case to the reporting person's completion of two years of continuous service (or less, in the event of a change in control) in the role of President and Chief Executive Officer. This award expires ten years from the date of grant.

Key Figures

Time-based stock options granted: 93,229 options Performance-based stock options granted: 124,305 options Exercise price per option: $49.6100 per share +3 more

6 metrics

Time-based stock options granted 93,229 options Employee Stock Option grant on 2026-08-05, vesting over four years

Performance-based stock options granted 124,305 options Employee Stock Option grant on 2026-08-05 with price and service conditions

Exercise price per option $49.6100 per share Conversion or exercise price for both Employee Stock Option awards

Option expiration date 2036-08-05 Both CEO stock option awards expire ten years from the grant date

Time-vested award start 8/5/2027 Vesting of 93,229 options commences on this date in four equal installments

Service period for performance award 2 years Continuous service as President and CEO required for performance-based vesting

Key Terms

Employee Stock Option (Right to Buy), vest and become exercisable, pre-specified levels, change in control

4 terms

Employee Stock Option (Right to Buy) financial

"security_title: Employee Stock Option (Right to Buy)"

vest and become exercisable financial

"Shares underlying the stock option vest and become exercisable in four equal annual installments"

pre-specified levels financial

"trading at certain pre-specified levels for 30 consecutive trading days"

change in control financial

"or less, in the event of a change in control) in the role of President"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stock option grants did Alkermes (ALKS) CEO Jackson Blair Curtis receive?

Jackson Blair Curtis received two Employee Stock Option awards on 2026-08-05: one for 93,229 options and another for 124,305 options, each over ordinary shares with a $49.6100 exercise price and expiration on 2036-08-05.

How do the time-based stock options for Alkermes (ALKS) CEO vest?

The time-based award of 93,229 stock options vests in four equal annual installments, commencing on 8/5/2027. Once vested, these options become exercisable at an exercise price of $49.6100 per ordinary share until 2036-08-05.

What performance conditions apply to the 124,305 Alkermes (ALKS) CEO stock options?

The 124,305 stock options vest in two tranches only if Alkermes’s ordinary shares trade at pre-specified price levels for 30 consecutive trading days, and after two years of continuous service as President and CEO, subject to change-in-control provisions.

Why were these stock options granted to the Alkermes (ALKS) CEO?

The filing states the awards were granted in connection with Jackson Blair Curtis’s appointment as President and Chief Executive Officer of Alkermes plc, aligning his compensation with company performance through equity-based incentives over a multi-year period.

What is the term of the new Alkermes (ALKS) CEO stock options?

Both stock option awards expire on 2036-08-05, giving Jackson Blair Curtis up to ten years from the grant date to exercise vested options at the $49.6100 per share exercise price, subject to each award’s vesting conditions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/07/2026 - 09:17 PM Accepted by SEC EDGAR 08/07/2026 - 09:17 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jackson Blair Curtis

(Last) (First) (Middle)

CONNAUGHT HOUSE

1 BURLINGTON ROAD

(Street)

DUBLIN 4 IRELAND

(City) (State) (Zip)

IRELAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
Alkermes plc. [ ALKS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO, Alkermes plc

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$49.61	08/05/2026		A(1)		93,229		(2)	08/05/2036	Ordinary Shares	93,229	$0	93,229	D
Employee Stock Option (Right to Buy)	$49.61	08/05/2026		A(1)		124,305		(3)	08/05/2036	Ordinary Shares	124,305	$0	124,305	D

Explanation of Responses:

1. This award was granted in connection with the reporting person's appointment as President and Chief Executive Officer.

2. Shares underlying the stock option vest and become exercisable in four equal annual installments, commencing on 8/5/2027.

3. Shares underlying the stock option shall vest and become exercisable, if at all, in two tranches based upon the closing price of an ordinary share of Alkermes plc, as reported by the Nasdaq Global Select Market or another national securities exchange on which Alkermes plc's ordinary shares are listed, trading at certain pre-specified levels for 30 consecutive trading days, subject in each case to the reporting person's completion of two years of continuous service (or less, in the event of a change in control) in the role of President and Chief Executive Officer. This award expires ten years from the date of grant.

	/s/ Shantale Greenson, attorney-in-fact for Blair C. Jackson	08/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)